SAN DIEGO, Dec. 8 /PRNewswire/ -- Trega Biosciences, Inc. (Nasdaq: TRGA),
today announced the addition Myra N. Williams, Ph.D. to its Board of
Directors. Additionally, Trega announced the resignation of Anders P. Wiklund
from the Board.
Dr. Williams was most recently the president and CEO of Molecular
Applications Group. Previously, Dr. Williams had served as Vice President and
Worldwide Director of R & D Information Systems for Glaxo Wellcome, as well as
Chief Information Officer of Glaxo Inc., prior to its merger with Wellcome.
She has also served as Executive Director of Information Resources and
Strategic Planning for Merck. At Merck, Dr. Williams pioneered the use of
remote data entry for clinical data and extended the use of molecular modeling
and drug design, among other accomplishments.
"I am delighted that Dr. Williams has agreed to join Trega's Board," said
Michael G. Grey, president and chief executive officer. "We will benefit
greatly from her experience as we continue to develop Trega's
information-driven drug discovery technology. On a different note, we are
sorry to lose Anders Wiklund from our Board. I would like to thank Anders for
his valuable contributions."
Trega also announced the retirement of its president of research and
development, Lawrence D. Muschek, Ph.D., effective December 31, 1999. Dr.
Muschek will continue to serve on the Board of Directors.
"Larry's contributions over that last few years have included playing
principal roles in the development of Trega's melanocortin receptor programs,
such as the sexual dysfunction program and in partnering the MC-4 obesity
program with Novartis Pharma AG. In addition, he played an important role in
the decision to acquire NaviCyte last year," Mr. Grey continued. "I look
forward to his continued counsel on the Board and wish him luck in his
retirement."
Trega Biosciences is a information-based technology company focused on
accelerating the process of drug discovery from disease targets to clinical
candidates by using small molecule combinatorial chemistry, high throughput
screening and predictive bioinformatics to rapidly create novel drug
candidates having greater chances of clinical success. In combination with
its wholly-owned subsidiary, NaviCyte, Trega offers integrated products and
services spanning the drug discovery process -- beginning with synthesizing
novel compounds to providing uniquely qualified drug leads -- to the
pharmaceutical and biopharmaceutical industries. Trega also uses its drug
discovery technologies in its internal development programs, which are focused
on discovering small molecules acting on melanocortin receptors, which may be
important in the treatment of inflammatory and metabolic diseases.
Except for the historical information contained herein, the matters
discussed in this news release are forward-looking statements that involve
risks and uncertainties, including whether the reported transition in
management and within the Board will occur without disrupting the Company's
business and operations, whether any proposed product can be successfully
formulated, scaled-up, developed, and commercialized, whether regulatory
approvals can be obtained, the impact of competitive products and pricing, the
financial condition of the Company in the future, whether any collaborations
or alliances will be successful, and other risks detailed from time to time in
Trega's Securities and Exchange Commission filings. These forward-looking
statements represent Trega's judgment as of the date of this release. Actual
results may differ materially from those projected. Trega disclaims, however,
any intent or obligation to update these forward-looking statements.
Trega's releases are on the World Wide Web at http://www.trega.com and PR
Newswire's fax-on-demand service at 1-800-758-5804, extension 374050.
SOURCE Trega Biosciences, Inc.
 back to top
Company News On-Call:
http://www.prnewswire.com/comp/374050.html or fax,
800-758-5804, ext. 374050
CONTACT:
Gerard A. Wills, Vice President, Finance &
CFO, 858-410-6695, or Cynthia Reindal, Corp. Communications &
Investor Relations, 858 410-6601, both of Trega Biosciences, Inc.
|
